Phase II trial of gefitinib in combination with bevacizumab as first‐line therapy for advanced non‐small‐cell lung cancer with activating EGFR gene mutations: The Okayama Lung Cancer Study Group trial 1001. J Thorac Oncol. International Association for the Study of